161 related articles for article (PubMed ID: 32579788)
1. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
2. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
4. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
6. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
7. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
8. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.
Li Z; Li Q; Wang G; Huang Y; Mao X; Zhang Y; Wang X
Am J Transl Res; 2017; 9(8):3776-3786. PubMed ID: 28861168
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
11. Small molecule modulators of Wnt/β-catenin signaling.
Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
[TBL] [Abstract][Full Text] [Related]
12. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway.
Wang T; Wang J; Ren W; Liu ZL; Cheng YF; Zhang XM
Thorac Cancer; 2020 Aug; 11(8):2316-2324. PubMed ID: 32657048
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
16. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.
Chen L; Wang L; Shen H; Lin H; Li D
Biochem Biophys Res Commun; 2017 Mar; 484(2):416-421. PubMed ID: 28137584
[TBL] [Abstract][Full Text] [Related]
17. The role of WNT/β-catenin signaling pathway and glutamine metabolism in the pathogenesis of CCl
El-Ashmawy NE; Al-Ashmawy GM; Fakher HE; Khedr NF
Cytokine; 2020 Dec; 136():155250. PubMed ID: 32882667
[TBL] [Abstract][Full Text] [Related]
18. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
[TBL] [Abstract][Full Text] [Related]
19. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]